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StenosisRetinoblastoma is a deadly eye cancer in children, leading to death in 50%–70% of children in undeveloped
nations. Unfortunately, this aggressive tumor is the most common intraocular malignancy worldwide. For the
last 2 decades, intravenous (IV) chemotherapy has been the mainstay of treatment for retinoblastomas. This
route has provided improved control in retinoblastoma, with sparing of the eye and vision in some cases.
More recently, intra-arterial chemotherapy (IAC) has become the ﬁrst line treatment for advanced and
refractory retinoblastoma in many centers worldwide. The advances in treatment along with early tumor
detection are responsible for the favorable prognosis found in developed nations. IAC classically uses the
ophthalmic artery (OA) in attempt to deliver the maximal dose of chemotherapy while minimizing systemic
complications. However, direct catheterization of the ophthalmic artery (OA) is not always possible. The
purpose of this article is to describe a case where the OA has been thrombosed and an alternative access route
using the middle meningeal artery (MMA) was used.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
Retinoblastoma is a deadly eye cancer in children, leading to death
in 50%–70% of children in undeveloped nations [1]. Unfortunately, this
aggressive tumor is the most common intraocular malignancy
worldwide. For the last 2 decades, intravenous (IV) chemotherapy
has been the mainstay of treatment for retinoblastomas [1–4]. This
route has provided improved control in retinoblastoma, with sparing
of the eye and vision in some cases. More recently, intra-arterial
chemotherapy (IAC) has become the ﬁrst line treatment for advanced
and refractory retinoblastoma in many centers worldwide [1–4]. The
advances in treatment along with early tumor detection are
responsible for the favorable prognosis found in developed nations.
IAC classically uses the ophthalmic artery (OA) in attempt to deliver
the maximal dose of chemotherapy while minimizing systemic
complications. However, direct catheterization of the ophthalmic
artery (OA) is not always possible. The purpose of this article is to.D. is a consultant at Covidien.
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B.V. This is an open access article udescribe a case where the OA has been thrombosed and an alternative
access route using the middle meningeal artery (MMA) was used.
Case presentation
The patient is an infant who was diagnosed with advanced
right-sided retinoblastoma. The patient was a candidate for IAC. The
patient was taken to the interventional suite for initiation of IAC.
Treatment
The technique used in the ﬁrst two sessions of IAC was the direct
OA catheterization. This technique consists of superselective cathe-
terization of the ostium of the ophthalmic artery under ﬂuoroscopic
guidance for focal delivery of chemotherapy. At the time of the third
IAC session, the angiography demonstrated complete occlusion of the
OA (Fig. 1). Therefore, we aimed to catheterize the OA through the
middle meningeal artery (MMA) if the communicating branch
between the two systems is sufﬁciently developed to permit it.
Selectively, the right external carotid artery (ECA) was catheter-
ized and the microcatheter was guided into the MMA via the internal
maxillary artery (Fig. 2). An angiogram performed then showed
collaterals from branch of the MMA reconstituting completely the
ophthalmic artery all the way to the central retinal artery (Fig. 3a).
Superselectively with a Prowler 10 and Synchro 10, the branch of the
MMA going all the way to the OA was catheterized. Then, intraarterialnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. a) Angiogram demonstrating a patent Ophthalmic artery at the time of the ﬁrst
chemotherapy session. b) Angiogram at follow-up showing the right internal carotid
artery with occlusion of the ophthalmic artery. At this point, the decision was made to
seek an alternative route for delivery.
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followed by another half an hour of IA infusion of topotecan 1 mg.
Control angiogram with selective right ECA injection showed
patency of the collateral to the OA (Fig. 3b). The IACwaswell tolerated
with no local side effects. No sever systemic complications including
neutropenia, vomiting, or alopecia, which commonly occur with IV
chemotherapy were noted. The patient was successfully treated and
discharged home without any complications. The tumor has
completely regressed and enucleation was avoided. He continued to
follow with his Ophthalmologist without any evidence tumor
recurrence at 1-year follow-up.Discussion
IAC came as a solution for the low success rate of chemoreduction in
treating advanced retinoblastoma particularly when vitreous micro-
metastasis was present [5]. Even more, IAC offers the advantage of
delivering ahigherdosedirectly to the tumorbedwithminimal systemic
toxic effects, reducing therefore the rate of cancer’s recurrence [6]. Direct
OA catheterization with microcatheter can achieve a technical success
rate of 98.5%–100% in expert hands [2]. This presumed combination of
efﬁcacy, safety, and precisionmakes IAC very appealing for dealingwith
retinoblastomas [1]. OA catheterization technique has been demon-
strated to be successful as primary therapy [2,3,7], especially with
advanced disease, in bilateral cases [8], and in refractory cases [2,7,8].
However, direct OA is not always feasible for a multitude of reasons.
First, the size of the OA in children can be too small for catheterization
[3]. Second, themajor blood supply to the globemight be derived froma
different artery, and ﬁnally, the angle between the OA and the ICA can
make the catheterization challenging [3]. Furthermore, if the ﬁrst
attempts have been successful, future treatment via direct catheteriza-
tion is not guaranteed for a variety of reasons, which include vasospasm
[3] and complete thrombosis of the OA as seen in the present case. In
these problematic situations, an alternative access route that ensures
the same fruitful outcomes as with direct OA catheterization is needed.
One solution would be the access to the globe by making use of the
communication between the ECA and the OA. A retrospective review of
110 retinoblastomas treated by at least 1 infusion by a vascular route
other than direct OA catheterization, reported a survival rate of 92.9%
(13/14 patients) with a tumor control in 17/18 eyes after a median
follow-up of 17.5 months [3]. The alternative routes included catheter-
ization through the MMA and balloon-assisted infusion.
The MMA may form an anastomosis with the lacrimal artery soon
after it branches off the OA. This branch, called the orbital branch of
the MMA, enters the orbit through the lateral aspect of the superior
orbital ﬁssure, and can be in many cases suitable for catheterization.
The chemotherapy drugs can be injected to ﬁll the lacrimal artery and
reﬂux into the OA, resulting in ﬂow of chemotherapy to the eye
through the normal ciliary and retinal circulation [3]. Rarely, theMMA
may give rise to the origin of the OA, which can be another alternative
route for IAC delivery to the eye [9,10]. In conclusion, the alternative
routes to direct OA catheterization have been proven safe, feasible,
and able to achieve excellent tumor control [3].
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Fig. 2. Angiogram showing the catheterization of the right external carotid artery where the microcatheter was guided into the middle meningeal artery via the internal maxillary
artery.
78 M. Zanaty et al. / Interdisciplinary Neurosurgery: Advanced Techniques and Case Management 2 (2015) 76–78Fig. 3. a) Angiogram showing the catheterization of the branch of the middle meningeal artery (where delivery of the chemotherapeutic regimen was performed) with retrograde
ﬁlling of the ophthalmic artery. b) Control angiogram showing patency of the collateral to the ophthalmic artery.
